New frontiers in focal therapy for prostate cancer: Prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging
Open Access
- 24 February 2021
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 12 (2), 61-68
- https://doi.org/10.5306/wjco.v12.i2.61
Abstract
Imaging has a central role in the context of focal therapy (FT) for prostate cancer (PCa). Prostate-specific membrane antigen (PSMA) positron emission tomography/magnetic resonance imaging (PET/MRI) is a novel imaging modality that combines the morpho-functional information of MRI with the molecular characterization of PET. Some papers reported the potential advantages of PSMA PET/MRI in different clinical scenarios. Limited evidence on PSMA PET/MRI is available in the setting of FT. PSMA PET/MRI can be an effective imaging modality for detecting primary PCa and seems to provide accurate local staging of primary PCa. PSMA PET/MRI also shows high performance for restaging and detecting tumor recurrence. The higher soft-tissue contrast and the reduction of ionizing radiation are the main advantages reported in the literature compared to PET/computed tomography. PSMA PET/MRI could represent a turning point in the management of patients with PCa in the context of FT. Further studies are needed to confirm its applications in this specific clinical setting.This publication has 38 references indexed in Scilit:
- Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-AnalysesCancers, 2020
- Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyThe Lancet, 2020
- Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-AnalysisCancers, 2019
- The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate CancerUrology, 2019
- 68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomyWorld Journal of Urology, 2019
- Impact of 68 Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2018
- PSMA expression: a potential ally for the pathologist in prostate cancer diagnosisScientific Reports, 2018
- Clinical perspectives of PSMA PET/MRI for prostate cancerClinics, 2018
- PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Guía de la eau para el cáncer de próstataActas Españolas de Psiquiatría, 2009